Table 2.
Primary and acquired drug resistance profiles of Mycobacterium tuberculosis, Shandong, China, 2004–2018a
| Drug resistance | New case, no., (%) n = 11,467 | Relapse case, no., (%) n = 1981 | P value |
|---|---|---|---|
| DR-TB | 2173 (18.95) | 505 (23.24) | P < 0.001 |
| Any resistance to first-line drugs | |||
| INH | 1232(10.74) | 333(16.81) | P < 0.001 |
| RIF | 508(4.43) | 223(11.26) | P < 0.001 |
| EMB | 174(1.52) | 68(3.43) | P < 0.001 |
| SM | 1482(12.92) | 329(16.61) | P < 0.001 |
| MR-TB (Total) | 1326(11.56) | 225(11.36) | 0.791 |
| INH | 445(3.88) | 82(4.14) | 0.584 |
| RIF | 90(0.78) | 29(1.46) | 0.003 |
| EMB | 20(0.17) | 9(0.45) | 0.013 |
| SM | 758(6.61) | 99(5.00) | 0.007 |
| Others | 13(0.11) | 6(0.30) | 0.038 |
| MDR-TB (Total) | 366(3.19) | 167(8.43) | P < 0.001 |
| MDR1:INH + RFP | 81(0.71) | 37(1.87) | P < 0.001 |
| MDR2:INH + RFP + EMB | 15(0.13) | 6(0.30) | 0.073 |
| MDR3:INH + RFP + EMB + SM | 83(0.72) | 33(1.67) | P < 0.001 |
| MDR4:INH + RFP + SM | 166(1.45) | 76(3.84) | P < 0.001 |
| Others | 21(0.18) | 15(0.76) | P < 0.001 |
| PDR-TB | 473(4.12) | 110(5.55) | 0.004 |
| PDR1:INH + EMB | 14(0.12) | 1(0.05) | 0.713 |
| PDR2:INH + SM | 391(3.41) | 77(3.89) | 0.285 |
| PDR3:RFP + EMB | 7(0.06) | 3(0.15) | 0.173 |
| PDR4:RFP + SM | 38(0.33) | 19(0.96) | P < 0.001 |
| PDR5:INH + EMB + SM | 16(0.14) | 5(0.25) | 0.240 |
| Others | 7(0.06) | 5(0.25) | 0.008 |
aEMB ethambutol, INH Isoniazid, RFP Rifampin, SM Streptomycin, TB Tuberculosis, DR-TB Drug-resistant tuberculosis, MR-TB Mono-resistant tuberculosis, MDR-TB Multi-resistant tuberculosis, PDR-TB Polydrug resistant tuberculosis